[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-myocardial-infarction-with-st-segment-elevation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-myocardial-infarction-with-st-segment-elevation":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100639639","phase-2-recombinant-human-thymosin-beta-4-for-injectionnl005-for-acute-myocardial-infarction-100639639",false,"NCT07586865","Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase IIc Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Recombinant Human Thymosin Beta 4 Injection (NL005) in Patients With Acute Myocardial Infarction","Inclusion Criteria:\n\n* Willing and able to provide written informed consent (by the participant or legally authorized representative)\n* Aged 18 to 75 years old, any sex\n* Diagnosis of ST-segment elevation myocardial infarction (STEMI) with electrocardiogram (ECG) meeting protocol-specified ST-elevation criteria, and scheduled to undergo primary percutaneous coronary intervention (PCI)\n* OR, regardless of ECG criteria, the participant has a completely or nearly completely blocked (TIMI flow grade 0 or 1) proximal or mid left anterior descending (LAD) coronary artery as the single culprit vessel\n* The blocked LAD artery has no visible collateral blood supply from other coronary arteries (Rentrop grade 0)\n* Total myocardial ischemic time (time from chest pain onset to guidewire passage during PCI) meets one of the following: 1. More than 2 hours and less than 6 hours of ischemic time, with either post-PCI LAD TIMI flow grade of 2 or less, or left ventricular ejection fraction (LVEF) of 50% or lower measured by cardiac ultrasound during PCI hospitalization; 2. Between 6 and 24 hours of ischemic time (inclusive)\n* Males and females of childbearing potential must agree to use adequate contraception (such as hormonal or barrier methods, or abstinence) throughout the study\n\nExclusion Criteria:\n\n* Prior history of acute myocardial infarction, chronic total coronary occlusion, coronary thrombolysis, PCI, or coronary artery bypass graft surgery\n* Diagnosis of severe acute heart failure (Killip class III or higher) or chronic heart failure (NYHA functional class III or higher)\n* Severe, uncontrolled arrhythmia that cannot be corrected\n* Presence of aortic dissection\n* Severe liver or kidney dysfunction\n* History of stroke within the past 6 months\n* Current or past diagnosis of any malignancy\n* Blood pressure that remains at or above 180 mmHg systolic and\u002For 110 mmHg diastolic despite adequate antihypertensive treatment\n* History of clinically significant allergic reaction, especially known allergy to protein or biologic drugs\n* Participation in another clinical study within 3 months before screening\n* Unable to undergo cardiac magnetic resonance (CMR) imaging (e.g., due to implanted metal devices, severe claustrophobia, or other contraindications)\n* Any other condition that the investigator believes makes participation unsuitable (for example, the need for urgent or planned revascularization of non-LAD coronary arteries within 3 months)","ALL","18 Years","75 Years",{"count":20,"type":21},189,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this phase IIc clinical trial is to learn if recombinant human thymosin beta 4 injection (NL005) works to treat heart damage in people who have had a serious type of heart attack called ST-segment elevation myocardial infarction (STEMI) and have been treated with emergency percutaneous coronary intervention (PCI, a procedure to open the blocked artery). It will also learn about the safety of NL005. The main questions it aims to answer are:\n\n* Does NL005 lower the size of permanent heart muscle damage measured by cardiac magnetic resonance (CMR) scan 90 days after treatment?\n* What medical problems do participants have when taking NL005?\n\nResearchers will compare two different doses of NL005 to a placebo (a look-alike substance that contains no drug) to see if NL005 works better to reduce heart damage caused by the heart attack.\n\nParticipants will:\n\n* Receive NL005 or placebo through a vein within 4 hours after the PCI procedure, then once a day for 7 days\n* Stay in the hospital for the first week for monitoring, blood draws, and electrocardiograms (heart tracings)\n* Have a CMR scan on Day 6 and Day 90 to measure the size of the heart injury\n* Return to the hospital for checkups on Day 30 and Day 90\n* Be contacted by the study team (by phone or online) 3 times during the first year and come back to the hospital on Day 360 to check long-term recovery",[27,28,29,30,31],"Acute Myocardial Infarction (AMI)","Acute Myocardial Infarction of Anterior Wall","Acute Myocardial Infarction With ST Elevation","Acute Myocardial Infarction of Left Ventricle","Acute Myocardial Infarction With ST Segment Elevation",[33,34,35],"AMI","CMR","cardioprotective","NOT_YET_RECRUITING","2026-05-08",{"date":39,"type":40},"2026-05-14","ACTUAL",{"date":42,"type":21},"2026-05-18",{"date":44,"type":21},"2028-05-17",{"name":46,"class":47},"Beijing Northland Biotech. Co., Ltd.","INDUSTRY",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":5},"100572315","heat-shock-protein-47-in-thrombosis-100572315","NCT06731673","Heat Shock Protein 47 in Thrombosis","Heat Shock Protein 47: A Novel Biomarker of Thrombosis Risk","Inclusion Criteria:\n\n* 18 years of age or older\n* Informed consent\n\nVTE group:\n\n* Deep vein thrombosis confirmed on ultrasonography OR\n* Pulmonary embolism confirmed on computed tomography angiography (CTA)\n\nAMI group:\n\n* ST-segment elevation on electrocardiogram (ECG) AND\n* Culprit lesion(s) on coronary angiography\n\nStroke group:\n\n* Stroke confirmed on magnetic resonance imaging AND\n* Atrial fibrillation (Detected on ECG, telemtry or Holter monitoring) AND\n* Stroke localisation classic for AFib: cortical, cerebellar, brainstem or subcortical \\>1.5 cm in diameter\n\nHealthy group:\n\n\\- Healthy\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* no informed consent\n* Known haematological disorders\n* Active haematological malignancy\n* Severe renal insufficiency defined as eGFR \\\u003C15 or dialysis\n\nVTE - Pulmonary embolism incidentally detected by CTA conducted for purposes unrelated to pulmonary embolism assessment without concomitant DVT\n\nAMI\n\n* Coronary dissection\n* Takotsubo cardiomyopathy\n\nStroke\n\n\\- Stroke from other causes, e.g. findings pointing towards large vessel disease\n\nHealthy\n\n* Known acute or chronic disease\n* Prior VTE, AMI, stroke or other thromboembolic event",true,{"count":58,"type":21},340,"OBSERVATIONAL","The goal of this observational study is to learn if the novel biomarker Heat shock protein 47 (HSP47) can be used as a prognostic marker for vascular disease in people with acute venous thromboembolism (VTE), myocardial infarction (AMI) or ischaemic stroke compared to healthy volunteers. The main questions it aims to answer are:\n\n1. Are platelet levels of HSP47 higher in patients with acute VTE, AMI or stroke, compared to healthy volunteers.\n2. Does platelet levels of HSP47 remain elevated in patients with acute thrombotic events compared to healthy volunteers at 3 and 12-months of follow-up.\n3. Are platelet levels of HSP47 postively associated with platelet function and negatively associated with fibrinolytic capacity in patients with an acute thrombotic event.\n\nParticipants with VTE, AMI or stroke will be giving a blood sample at diagnosis and again after 3 and 12 months of follow-up. Healthy volunteers will be giving a blood sample once.",[62,31,63],"Venous Thromboembolism (VTE)","Stroke (in Patients With Atrial Fibrillation)",[65,66,67,68,69,70,33,71],"HSP47","Heat Shock Protein 47","Biomarker","Novel biomarker","Trombosis","VTE","Stroke","RECRUITING","2025-08-15",{"date":75,"type":40},"2025-08-21",{"date":77,"type":40},"2024-12-09",{"date":79,"type":21},"2027-08-31",{"name":81,"class":82},"University of Aarhus","OTHER"]